

27 Jun 2021 I

## **Quick Listen: Scrip's Five Must-Know Things**

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer's CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 June 2021, including: a look at pharma CEO pay; *Pfizer Inc.*'s CEO gives the inside track on COVID-19 vaccine development; *GlaxoSmithKline plc* elaborates on its restructuring and strategic plans; and *Kite Pharma, Inc.* talks about its cell therapy plans under *Gilead Sciences, Inc.* 

These and all other podcasts are available on the Informa Pharma Intelligence channel on <u>Apple Podcasts</u>, <u>Google Podcasts</u>, <u>SoundCloud</u> and <u>TuneIn</u> - and also now on <u>Spotify Podcasts</u> - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Titans Of Pharma 2021: J&J's Gorsky Tops Big Pharma Remuneration*" - Scrip, 22 Jun, 2021.)

(Also see "<u>How Pfizer Crafted Its Own 'Operation Warp Speed' For The COVID-19 Vaccine</u>" - Scrip, 24 Jun, 2021.)

(Also see "'New GSK' Still Has Some Convincing To Do" - Scrip, 24 Jun, 2021.)

(Also see "GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities" - Scrip,



23 Jun, 2021.)

(Also see "*Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy*" - Scrip, 21 Jun, 2021.)

Click here to explore this interactive content online